{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:50:33Z","timestamp":1781956233519,"version":"3.54.5"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1007\/s12282-026-01868-x","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T12:29:47Z","timestamp":1779107387000},"page":"820-828","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Limits of substitution and context-dependent selective omission of Oncotype DX recurrence score testing"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8935-0768","authenticated-orcid":false,"given":"Yoshiya","family":"Horimoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-8670-4357","authenticated-orcid":false,"given":"Ryoko","family":"Semba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5946-3742","authenticated-orcid":false,"given":"Takeshi","family":"Ushigusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2163-7989","authenticated-orcid":false,"given":"Hiroki","family":"Kusama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3450-4533","authenticated-orcid":false,"given":"Takashi","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"key":"1868_CR1","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1007\/s10549-013-2666-z","volume":"141","author":"JJ Carlson","year":"2013","unstructured":"Carlson JJ, Roth JA. The impact of the Oncotype Dx breast cancer assay in clinical practice: a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;141:13\u201322.","journal-title":"Breast Cancer Res Treat"},{"key":"1868_CR2","doi-asserted-by":"publisher","first-page":"2250","DOI":"10.1038\/bjc.2013.207","volume":"108","author":"S Holt","year":"2013","unstructured":"Holt S, Bertelli G, Humphreys I, Valentine W, Durrani S, Pudney D, et al. A decision impact, decision conflict and economic assessment of routine Oncotype DX testing of 146 women with node-negative or pNImi, ER-positive breast cancer in the U.K. Br J Cancer. 2013;108:2250\u20138.","journal-title":"Br J Cancer"},{"key":"1868_CR3","doi-asserted-by":"publisher","first-page":"464","DOI":"10.21873\/cdp.10349","volume":"4","author":"Y Nozaki","year":"2024","unstructured":"Nozaki Y, Horimoto Y, Semba R, Ueki Y, Ishizuka Y, Onagi H, et al. Attempt to substitute the oncotype DX breast recurrence Score(\u00ae) Test by histopathological factors and MUC1 protein expression. Cancer Diagn Progn. 2024;4:464\u20139.","journal-title":"Cancer Diagn Progn"},{"key":"1868_CR4","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41523-024-00700-z","volume":"10","author":"M Goyal","year":"2024","unstructured":"Goyal M, Marotti JD, Workman AA, Tooker GM, Ramin SK, Kuhn EP, et al. A multi-model approach integrating whole-slide imaging and clinicopathologic features to predict breast cancer recurrence risk. NPJ Breast Cancer. 2024;10:93.","journal-title":"NPJ Breast Cancer"},{"key":"1868_CR5","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1186\/s13058-024-01911-9","volume":"26","author":"Y Kook","year":"2024","unstructured":"Kook Y, Lee Y, Chu C, Jang J, Baek S, Bae S, et al. Differentiating HER2-low and HER2-zero tumors with 21-gene multigene assay in 2,295\u00a0h\u2009+\u2009HER2- breast cancer: a retrospective analysis. BCR. 2024;26:154.","journal-title":"BCR"},{"key":"1868_CR6","doi-asserted-by":"publisher","first-page":"3984","DOI":"10.1245\/s10434-025-17012-6","volume":"32","author":"P Borowsky","year":"2025","unstructured":"Borowsky P, Hernandez A, Kesmodel S, Goel N. Genetic ancestry and 21-Gene Oncotype DX breast cancer recurrence scores. Ann Surg Oncol. 2025;32:3984\u201390.","journal-title":"Ann Surg Oncol"},{"key":"1868_CR7","doi-asserted-by":"publisher","first-page":"100309","DOI":"10.1016\/j.labinv.2023.100309","volume":"104","author":"H Tyburski","year":"2024","unstructured":"Tyburski H, Karakas C, Finkelman B, Turner B, Zhang H, Hicks D. In ER-positive, HER2-negative breast cancers, HER2 mRNA levels correlate better with clinicopathologic features and Oncotype DX Recurrence score than HER2 immunohistochemistry. Lab Invest. 2024;104:100309.","journal-title":"Lab Invest"},{"key":"1868_CR8","doi-asserted-by":"crossref","unstructured":"Miglietta F, Dieci M, Giarratano T, Torri V, Giuliano M, Zustovich F et al. Association of tumor-infiltrating lymphocytes with recurrence score in hormone receptor-positive\/HER2-negative breast cancer: analysis of four prospective studies. Eur J Cancer (Oxford, England: 1990). 2023;195:113399.","DOI":"10.1016\/j.ejca.2023.113399"},{"key":"1868_CR9","doi-asserted-by":"publisher","first-page":"e72","DOI":"10.5858\/arpa.2023-0576-OA","volume":"149","author":"I Lagerstrom","year":"2025","unstructured":"Lagerstrom I, Neelon D, Wendzel N, Lipkowitz S, Moncur J, Uiterwaal S, et al. Quality assurance model for breast cancer prognostication using the modified magee equations. Arch Pathol Lab Med. 2025;149:e72\u20137.","journal-title":"Arch Pathol Lab Med"},{"key":"1868_CR10","doi-asserted-by":"publisher","first-page":"330","DOI":"10.1186\/s12885-023-10796-4","volume":"23","author":"S Ma","year":"2023","unstructured":"Ma S, Gill J, Yendamuri K, Chatterjee U, Waldman O, Dunne-Jaffe C, et al. Association of progesterone receptor status with 21-gene recurrence score and survival among patients with estrogen receptor-positive breast cancer. BMC Cancer. 2023;23:330.","journal-title":"BMC Cancer"},{"key":"1868_CR11","doi-asserted-by":"publisher","first-page":"100164","DOI":"10.1016\/j.modpat.2023.100164","volume":"36","author":"Y Hu","year":"2023","unstructured":"Hu Y, Jones D, Zhao W, Tozbikian G, Wesolowski R, Parwani A, et al. Incidence, clinicopathologic features, HER2 fluorescence in situ hybridization profile, and Oncotype DX results of human epidermal growth factor receptor 2-low breast cancers: experience from a single academic center. Mod Pathol. 2023;36:100164.","journal-title":"Mod Pathol"},{"key":"1868_CR12","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.suronc.2020.01.007","volume":"34","author":"M Pomponio","year":"2020","unstructured":"Pomponio M, Burkbauer L, Goldbach M, Keele L, Allison K, Li Y, et al. Is there an association between body mass index and 21-gene recurrence score? Surg Oncol. 2020;34:74\u20139.","journal-title":"Surg Oncol"},{"key":"1868_CR13","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jss.2015.05.034","volume":"198","author":"D Carr","year":"2015","unstructured":"Carr D, Vera N, Sun W, Lee M, Hoover S, Fulp W, et al. Menopausal status does not predict Oncotype DX recurrence score. J Surg Res. 2015;198:27\u201333.","journal-title":"J Surg Res"},{"key":"1868_CR14","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1245\/s10434-018-6440-7","volume":"25","author":"K Park","year":"2018","unstructured":"Park K, Chen Y, Chitale D, Choi S, Ali H, Nathanson S, et al. Utilization of the 21-Gene recurrence score in a diverse breast cancer patient population: development of a clinicopathologic model to predict high-risk scores and response to neoadjuvant chemotherapy. Ann Surg Oncol. 2018;25:1921\u20137.","journal-title":"Ann Surg Oncol"},{"key":"1868_CR15","doi-asserted-by":"publisher","first-page":"556","DOI":"10.1038\/modpathol.2011.194","volume":"25","author":"G Acs","year":"2012","unstructured":"Acs G, Esposito N, Kiluk J, Loftus L, Laronga C. A mitotically active, cellular tumor stroma and\/or inflammatory cells associated with tumor cells may contribute to intermediate or high Oncotype DX Recurrence Scores in low-grade invasive breast carcinomas. Mod Pathol 2012;25:556\u201366.","journal-title":"Mod Pathol"},{"key":"1868_CR16","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s10549-018-5013-6","volume":"173","author":"P Jerevall","year":"2019","unstructured":"Jerevall P, Brock J, Palazzo J, Wieczorek T, Misialek M, Guidi A, et al. Discrepancy in risk assessment of hormone receptor positive early-stage breast cancer patients using breast cancer index and recurrence score. Breast Cancer Res Treat. 2019;173:375\u201383.","journal-title":"Breast Cancer Res Treat"},{"key":"1868_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.breast.2019.05.006","volume":"46","author":"A Orucevic","year":"2019","unstructured":"Orucevic A, Bell J, King M, McNabb A, Heidel R. Nomogram update based on TAILORx clinical trial results - Oncotype DX breast cancer recurrence score can be predicted using clinicopathologic data. Breast (Edinburgh Scotland). 2019;46:116\u201325.","journal-title":"Breast (Edinburgh Scotland)"},{"key":"1868_CR18","doi-asserted-by":"publisher","first-page":"e70818","DOI":"10.1002\/cam4.70818","volume":"14","author":"J Song","year":"2025","unstructured":"Song J, Yang L, Feng Z, Jiang L. Nomogram development for assessing oncotype DX recurrence scores in breast cancer: a Chinese Population Study. Cancer Med. 2025;14:e70818.","journal-title":"Cancer Med"},{"key":"1868_CR19","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1007\/s12282-024-01616-z","volume":"31","author":"A Shibata","year":"2024","unstructured":"Shibata A, Tamura N, Kinowaki K, Nishikawa A, Tanaka K, Kobayashi Y, et al. Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer. Breast Cancer (Tokyo Japan). 2024;31:1018\u201327.","journal-title":"Breast Cancer (Tokyo Japan)"},{"key":"1868_CR20","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.5858\/arpa.2021-0367-OA","volume":"146","author":"A Mohamed","year":"2022","unstructured":"Mohamed A, Kousar A, Wong J, Vohra N, Muzaffar M, Geradts J. Pathobiologic stratification of Oncotype DX recurrence scores and comparative validation of 3 surrogate models. Arch Pathol Lab Med. 2022;146:1258\u201367.","journal-title":"Arch Pathol Lab Med"},{"key":"1868_CR21","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1111\/tbj.14217","volume":"27","author":"M Davey","year":"2021","unstructured":"Davey M, Ryan \u00c9, Abd Elwahab S, Elliott J, McAnena P, Sweeney K, et al. Clinicopathological correlates, oncological impact, and validation of Oncotype DX\u2122 in a European Tertiary Referral Centre. Breast J. 2021;27:521\u20138.","journal-title":"Breast J"},{"key":"1868_CR22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1007\/s12282-020-01163-3","volume":"28","author":"A Glasgow","year":"2021","unstructured":"Glasgow A, Sechrist H, Bomeisl P, Gilmore H, Harbhajanka A. Correlation between modified Magee equation-2 and Oncotype-Dx recurrence scores using both traditional and TAILORx cutoffs and the clinical application of the Magee Decision Algorithm: a single institutional review. Breast Cancer (Tokyo Japan). 2021;28:321\u20138.","journal-title":"Breast Cancer (Tokyo Japan)"},{"key":"1868_CR23","first-page":"490","volume":"31","author":"R Bhargava","year":"2023","unstructured":"Bhargava R, Dabbs D. The story of the magee equations: the ultimate in applied immunohistochemistry. AIMM. 2023;31:490\u20139.","journal-title":"AIMM"},{"key":"1868_CR24","doi-asserted-by":"publisher","first-page":"1611735","DOI":"10.3389\/pore.2024.1611735","volume":"30","author":"D Deme","year":"2024","unstructured":"Deme D, Tamaskovics B, Jammoul N, Kov\u00e1cs S, Kayode E, Grice J, et al. Association between pathological characteristics and recurrence score by OncotypeDX in resected T1-3 and N0-1 breast cancer: a real-life experience of a North Hungarian regional center. Pathol Oncol Res. 2024;30:1611735.","journal-title":"Pathol Oncol Res"},{"key":"1868_CR25","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13058-022-01571-7","volume":"24","author":"M Crager","year":"2022","unstructured":"Crager M, Wijayawardana S, Gruver A, Blacklock A, Russell C, Baehner F, et al. Population-based estimate for the correlation of the Oncotype Dx Breast Recurrence Score\u00ae result and Ki-67 IHC MIB-1 pharmDx in HR+, HER2-, node-positive early breast cancer. Breast Cancer Res. 2022;24:74.","journal-title":"Breast Cancer Res"},{"key":"1868_CR26","doi-asserted-by":"publisher","first-page":"5563","DOI":"10.21873\/anticanres.16758","volume":"43","author":"J Chu","year":"2023","unstructured":"Chu J, DO J, Kim DOS. Prediction of Oncotype DX recurrence score by evaluating the peritumoral tumor budding in early-stage breast carcinoma. Anticancer Res. 2023;43:5563\u201372.","journal-title":"Anticancer Res"},{"key":"1868_CR27","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1159\/000370341","volume":"38","author":"T Grenader","year":"2015","unstructured":"Grenader T, Plotkin Y, Geffen D. The preoperative neutrophil\/lymphocyte ratio does not correlate with the 21-gene recurrence score in estrogen receptor-positive breast cancer patients. Oncol Res Treat. 2015;38:24\u20137.","journal-title":"Oncol Res Treat"},{"key":"1868_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3233\/BD-201011","volume":"41","author":"B Finkelman","year":"2022","unstructured":"Finkelman B, Meindl A, LaBoy C, Griffin B, Narayan S, Brancamp R, et al. Correlation of manual semi-quantitative and automated quantitative Ki-67 proliferative index with OncotypeDXTM recurrence score in invasive breast carcinoma. Breast Dis. 2022;41:55\u201365.","journal-title":"Breast Dis"},{"key":"1868_CR29","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.2217\/bmm-2019-0209","volume":"13","author":"S Wu","year":"2019","unstructured":"Wu S, Zhang W, Wang J, Lian C, Sun J, Chen Y, et al. Progesterone receptor status and tumor grade predict the 21-gene recurrence score of invasive lobular breast cancer. Biomark Med. 2019;13:1005\u201312.","journal-title":"Biomark Med"},{"key":"1868_CR30","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-017-4326-1","volume":"165","author":"G Turashvili","year":"2017","unstructured":"Turashvili G, Brogi E, Morrow M, Hudis C, Dickler M, Norton L, et al. The 21-gene recurrence score in special histologic subtypes of breast cancer with favorable prognosis. Breast Cancer Res Treat. 2017;165:65\u201376.","journal-title":"Breast Cancer Res Treat"},{"key":"1868_CR31","doi-asserted-by":"publisher","first-page":"1546","DOI":"10.5858\/arpa.2014-0557-OA","volume":"139","author":"P Bomeisl","year":"2015","unstructured":"Bomeisl P, Thompson C, Harris L, Gilmore H. Comparison of Oncotype DX recurrence score by histologic types of breast carcinoma. Arch Pathol Lab Med. 2015;139:1546\u20139.","journal-title":"Arch Pathol Lab Med"},{"key":"1868_CR32","first-page":"3","volume":"159","author":"M Luj\u00e1n","year":"2023","unstructured":"Luj\u00e1n M, Mor\u00e1n D, Preciado B, Lema C, Fern\u00e1ndez M, Egurrola J, et al. Concordance between 21-gene recurrence score assay and clinicopathological predictive models in early-breast cancer patients cared for at a cancer center in Colombia. Gac Med Mex. 2023;159:3\u20139.","journal-title":"Gac Med Mex"},{"key":"1868_CR33","doi-asserted-by":"publisher","first-page":"2199","DOI":"10.1111\/tbj.14068","volume":"26","author":"S Kapadia","year":"2020","unstructured":"Kapadia S, Gudiwada S, Kaji A, Chlebowski R, Venegas R, Ozao-Choy J, et al. Can Oncotype DX testing be omitted in invasive breast cancer patients with clinicopathologic factors predicting very high pretest probability of a concordant result? Breast J. 2020;26:2199\u2013202.","journal-title":"Breast J"},{"key":"1868_CR34","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1016\/j.clbc.2015.04.006","volume":"15","author":"M Gage","year":"2015","unstructured":"Gage M, Rosman M, Mylander W, Giblin E, Kim H, Cope L, et al. A validated model for identifying patients unlikely to benefit from the 21-Gene recurrence score assay. Clin Breast Cancer. 2015;15:467\u201372.","journal-title":"Clin Breast Cancer"},{"key":"1868_CR35","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1080\/14737140.2024.2393749","volume":"24","author":"K Liu","year":"2024","unstructured":"Liu K, Chen G, Chen X, Wu S. Tumor grade and progesterone receptor status in predicting benefit of chemotherapy in high genomic risk breast cancer. Expert Rev Anticancer Ther. 2024;24:1021\u20138.","journal-title":"Expert Rev Anticancer Ther"},{"key":"1868_CR36","first-page":"1278","volume":"31","author":"A Awan","year":"2024","unstructured":"Awan A, Saunders D, Pond G, Hamm C, Califaretti N, Mates M, et al. Does pre-emptive availability of PREDICT 2.1 results change ordering practices for Oncotype DX? A Multi-Center Prospective Cohort Study. Curr Nncol (Toronto). 2024;31:1278\u201390.","journal-title":"Curr Nncol (Toronto)"},{"key":"1868_CR37","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/modpathol.2008.54","volume":"21","author":"MB Flanagan","year":"2008","unstructured":"Flanagan MB, Dabbs DJ, Brufsky AM, Beriwal S, Bhargava R. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255\u201361.","journal-title":"Mod Pathol"},{"key":"1868_CR38","doi-asserted-by":"publisher","first-page":"468","DOI":"10.1111\/his.15234","volume":"85","author":"A Lashen","year":"2024","unstructured":"Lashen A, Toss M, Miligy I, Rewcastle E, Kiraz U, Janssen E, et al. Nottingham prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: a validation study. Histopathology. 2024;85:468\u201377.","journal-title":"Histopathology"},{"key":"1868_CR39","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1002\/cncr.23225","volume":"112","author":"I Wolf","year":"2008","unstructured":"Wolf I, Ben-Baruch N, Shapira-Frommer R, Rizel S, Goldberg H, Yaal-Hahoshen N, et al. Association between standard clinical and pathologic characteristics and the 21-gene recurrence score in breast cancer patients: a population-based study. Cancer. 2008;112:731\u20136.","journal-title":"Cancer"},{"key":"1868_CR40","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1097\/PAI.0000000000000261","volume":"25","author":"L Lee","year":"2017","unstructured":"Lee L, Swanson P, Tang P, Bigras G, Yang H. Association between phosphorylated histone H3 and Oncotype DX recurrence scores in breast cancer. Appl Immunohistochem Mol morphology. 2017;25:25\u201331.","journal-title":"Appl Immunohistochem Mol morphology"},{"key":"1868_CR41","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1007\/s12282-018-0860-x","volume":"25","author":"M Sughayer","year":"2018","unstructured":"Sughayer M, Alaaraj R, Alsughayer A. Applying new Magee equations for predicting the Oncotype Dx recurrence score. Breast Cancer (Tokyo Japan). 2018;25:597\u2013604.","journal-title":"Breast Cancer (Tokyo Japan)"},{"key":"1868_CR42","doi-asserted-by":"publisher","first-page":"1697","DOI":"10.5858\/2009-0439-OAR.1","volume":"134","author":"J Auerbach","year":"2010","unstructured":"Auerbach J, Kim M, Fineberg S. Can features evaluated in the routine pathologic assessment of lymph node-negative estrogen receptor-positive stage I or II invasive breast cancer be used to predict the Oncotype DX recurrence score? Arch Pathol Lab Med. 2010;134:1697\u2013701.","journal-title":"Arch Pathol Lab Med"},{"key":"1868_CR43","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s10549-018-05088-6","volume":"176","author":"M Mutonga","year":"2019","unstructured":"Mutonga M, Speedy S, Rademaker A, Liu D, Uthe R, Jain S, et al. Relationship of pathological features and a 21 gene expression assay in younger versus older women with node-negative endocrine receptor-positive breast cancer. Breast Cancer Res Treat. 2019;176:95\u2013100.","journal-title":"Breast Cancer Res Treat"},{"key":"1868_CR44","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1177\/1066896909340274","volume":"17","author":"K Gwin","year":"2009","unstructured":"Gwin K, Pinto M, Tavassoli F. Complementary value of the Ki-67 proliferation index to the oncotype DX recurrence score. Int J Surg Pathol. 2009;17:303\u201310.","journal-title":"Int J Surg Pathol"},{"key":"1868_CR45","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1111\/ajco.12779","volume":"14","author":"A Tan","year":"2018","unstructured":"Tan A, Li B, Nahar K, Danieletto S, Fong E, Currer T, et al. Correlating Ki67 and other prognostic markers with Oncotype DX recurrence score in early estrogen receptor-positive breast cancer. Asia-Pac J Clin Oncol. 2018;14:e161\u20136.","journal-title":"Asia-Pac J Clin Oncol"},{"key":"1868_CR46","doi-asserted-by":"publisher","first-page":"152410","DOI":"10.1016\/j.anndiagpath.2024.152410","volume":"74","author":"K Sotome","year":"2025","unstructured":"Sotome K, Maeda H, Yanagisawa T, Harada Y, Mae Y, Ogiso M, et al. Recurrence score-predicted value derived from estrogen receptor, tumor-infiltrating lymphocytes, progesterone receptor, and Ki-67 may substitute for the Oncotype DX recurrence score in estrogen receptor (ER)+\/human epidermal growth factor receptor 2 (HER2)- breast cancer. Annals Diagn Pathol. 2025;74:152410.","journal-title":"Annals Diagn Pathol"},{"key":"1868_CR47","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/jclinpath-2015-203012","volume":"68","author":"F Vera-Badillo","year":"2015","unstructured":"Vera-Badillo F, Chang M, Kuruzar G, Ocana A, Templeton A, Seruga B, et al. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer. J Clin Pathol. 2015;68:839\u201343.","journal-title":"J Clin Pathol"},{"key":"1868_CR48","doi-asserted-by":"publisher","first-page":"978","DOI":"10.3109\/07357907.2010.496754","volume":"28","author":"PTJWDGH X","year":"2010","unstructured":"X PTJWDGH. A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer. Cancer Invest. 2010;28:978\u201382.","journal-title":"Cancer Invest"},{"key":"1868_CR49","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1038\/modpathol.2015.50","volume":"28","author":"T BM","year":"2015","unstructured":"BM T, KA S, MC PT. Use of modified Magee equations and histologic criteria to predict the Oncotype DX recurrence score. Mod Pathol. 2015;28:921\u201331.","journal-title":"Mod Pathol"},{"key":"1868_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1007\/s10549-017-4619-4","volume":"168","author":"KSXH ET","year":"2018","unstructured":"ET KSXH. Relationship of histologic grade and histologic subtype with oncotype Dx recurrence score; retrospective review of 863 breast cancer oncotype Dx results. Breast Cancer Res Treat. 2018;168:29\u201334.","journal-title":"Breast Cancer Res Treat"},{"key":"1868_CR51","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1038\/modpathol.2008.54","volume":"21","author":"F MB","year":"2008","unstructured":"MB F, DJ D, AM B. Histopathologic variables predict Oncotype DX recurrence score. Mod Pathol. 2008;21:1255\u201361.","journal-title":"Mod Pathol"},{"key":"1868_CR52","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.hemonc.2015.12.001","volume":"9","author":"L Chaudhary","year":"2016","unstructured":"Chaudhary L, Jawa Z, Szabo A, Visotcky A, Chitambar C. Relevance of progesterone receptor immunohistochemical staining to Oncotype DX recurrence score. Hematol Oncol Stem Cell Ther. 2016;9:48\u201354.","journal-title":"Hematol Oncol Stem Cell Ther"},{"key":"1868_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/cac2.12024","volume":"40","author":"YZ Y Z","year":"2020","unstructured":"Y Z YZ. Ki-67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: a consecutive cohort study. Cancer Commun (London England). 2020;40:181\u201393.","journal-title":"Cancer Commun (London England)"},{"key":"1868_CR54","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.breast.2022.03.007","volume":"63","author":"C Wang","year":"2022","unstructured":"Wang C, Xu Y, Lin Y, Zhou Y, Mao F, Zhang X, et al. Comparison of CTS5 risk model and 21-gene recurrence score assay in large-scale breast cancer population and combination of CTS5 and recurrence score to develop a novel nomogram for prognosis prediction. Breast (Edinburgh Scotland). 2022;63:61\u201370.","journal-title":"Breast (Edinburgh Scotland)"},{"key":"1868_CR55","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/his.13690","volume":"73","author":"D Dabbs","year":"2018","unstructured":"Dabbs D, Clark B, Serdy K, Onisko A, Brufsky A, Smalley S, et al. Pathologist\u2019s health-care value in the triage of Oncotype DX(\u00ae) testing: a value-based pathology study of tumour biology with outcomes. Histopathology. 2018;73:692\u2013700.","journal-title":"Histopathology"},{"key":"1868_CR56","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1111\/tbj.13117","volume":"24","author":"P Wilson","year":"2018","unstructured":"Wilson P, Chagpar A, Cicek A, Bossuyt V, Buza N, Mougalian S, et al. Breast cancer histopathology is predictive of low-risk Oncotype Dx recurrence score. Breast J. 2018;24:976\u201380.","journal-title":"Breast J"},{"key":"1868_CR57","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1007\/s10549-018-4955-z","volume":"172","author":"J Huang","year":"2018","unstructured":"Huang J, Kizy S, Marmor S, Altman A, Blaes A, Beckwith H, et al. Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma. Breast Cancer Res Treat. 2018;172:671\u20137.","journal-title":"Breast Cancer Res Treat"},{"key":"1868_CR58","doi-asserted-by":"publisher","first-page":"735","DOI":"10.5858\/arpa.2017-0169-OA","volume":"142","author":"S Kizy","year":"2018","unstructured":"Kizy S, Huang J, Marmor S, Blaes A, Yuan J, Beckwith H, et al. Distribution of 21-Gene Recurrence scores among breast cancer histologic subtypes. Arch Pathol Lab Med. 2018;142:735\u201341.","journal-title":"Arch Pathol Lab Med"},{"key":"1868_CR59","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/modpathol.2013.36","volume":"26","author":"ME Klein","year":"2013","unstructured":"Klein ME, Dabbs DJ, Shuai Y, Brufsky AM, Jankowitz R, Puhalla SL, et al. Prediction of the Oncotype DX recurrence score: use of pathology-generated equations derived by linear regression analysis. Mod Pathol. 2013;26:658\u201364.","journal-title":"Mod Pathol"}],"container-title":["Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12282-026-01868-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12282-026-01868-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,20]],"date-time":"2026-06-20T11:02:45Z","timestamp":1781953365000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12282-026-01868-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":59,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,7]]}},"alternative-id":["1868"],"URL":"https:\/\/doi.org\/10.1007\/s12282-026-01868-x","relation":{},"ISSN":["1340-6868","1880-4233"],"issn-type":[{"value":"1340-6868","type":"print"},{"value":"1880-4233","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"4 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yoshiya Horimoto is an Editorial Board member of Breast Cancer and a corresponding author of this article. To minimize bias, he was excluded from all editorial decision-making related to the acceptance of this article for publication. The remaining authors declare no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}